铜绿假单胞菌PA—MSHA菌毛株菌苗辅助治疗恶性淋巴瘤和？…

为评价铜绿假单胞菌ＭＳＨＡ菌毛株菌苗（ＰＡ－ＭＡＨＡ菌苗）作为免疫调节剂的有效性和安全性，采用非盲法随机对照试验，分别对８８例恶性淋巴瘤和８９例肺癌患者进行了临床实验研究，试验组给予化疗＋ＰＡ。ＭＨＳＡ菌苗，对照组单用化疗。结果：经化疗＋ＰＡ－ＭＳＨＡ治疗，恶性淋巴瘤和肺癌试验组的治疗有效率（ＣＲ＋ＰＲ）分别为９５．５６％（４３／４５）和５９．０９％（２６／４４），其对照组分别为６９．７７％（３０

A clinical study on PA-MSHA vaccine used for adjuvant therapy of lymphoma and lung cancer]

The objective of this study was to evaluate the effectiveness and safety of pseudomonas aeruginosa MSHA vaccine (PA-MSHA vaccine) used as an immune modulator. The study was carried out after the design of a non-blind, randomized controlled trial. The malignant lymphoma patients were divided into experiment group (45 cases) and control group (43 cases). Likewise were distributed the lung cancer patients: 44 cases in experiment group and 45 cases in control group. The two experiment groups received chemotherapy + PA-MSHA vaccine. The two control groups were given chemotherapy alone. The results showed that the clinical efficacy rate was 95.56% for the exp. group and 69.77% (P < 0.01) for the control group of the malignant lymphoma cases; the clinical efficacy rate was 59.09% for the exp. group and 42.22% (P < 0.01) for the control group of the lung cancer cases. The infection rate was 17.78% for the exp. group and 37.21% (P < 0.05) for the control group of the malignant lymphoma cases; the infection rate was 15.91% for the exp. group and 40.00% (P < 0.05) for the control group of the lung cancer cases. The comprehensive immune effectiveness rates for the exp. group and control group of the malignant lymphoma cases were 77.78% and 23.26% (P < 0.01) respectively. The comprehensive immune effectiveness rates for the exp. group and control group of the lung cancer cases were 84.09% and 35.56% (P < 0.01) respectively. Adverse reactions were found in 5 cases, of which, one was given medical care while the others automatically recovered. These results indicate that PA-MSHA vaccine, as a new kind of immune modulator, can improve the effectiveness of treatment for tumor with low adverse reaction rate.